Retrotope Advances RT001 in Clinical Trials to Treat Friedreich's ataxia

(Ref: Marketwired) February 22nd, 2016

LOS ALTOS, CA--(Marketwired) - Retrotope, a privately held clinical stage pharmaceutical company, today announced the successful completion of the first dose cohort and the opening of patient enrollment for the highest dose cohort in its ongoing 28-day study of orally dosed RT001 in Friedreich's ataxia (FA) patients. RT001 was well tolerated and no serious adverse events or dose limiting toxicities were observed.


 Retrotope Advances RT001 in Clinical Trials to Treat Friedreich's ataxia